Navigation Links
Hotspur Technologies Continues to Bring Innovations to Peripheral Vascular Market
Date:1/10/2011

MOUNTAIN VIEW, Calif., Jan. 10, 2011 /PRNewswire/ -- Hotspur Technologies, Inc. announced today that Dr. Bruce Lin, M.D., and Dr. Stephen Liu, M.D., Interventional Radiologists at Lifelink Interventional Center in Modesto, California, performed the first commercial deployment of the company's GPSCath™ Balloon Dilatation Catheter.  This new device enables, for the first time, multiple vascular procedures to be performed with one catheter, potentially reducing procedure time and expense for both patients and medical professionals.  

The GPSCath™ is a two-in-one device that allows physicians to perform high-pressure angioplasty and inject physician-specified fluids such as contrast while maintaining guidewire position.  

"The Hotspur GPSCath™ balloon is a superior alternative to a non-compliant ultra-high-pressure legacy devices currently in use," said Dr. Lin. "This is because the flexible nature of the Hotspur device allows tactile and visual feedback on the stenotic lesion, while still providing the performance of a ultra-high-pressure angioplasty balloon.  In addition, the value added feature enables operators to conveniently maintain guidewire position while delivering therapeutic drugs and evaluating results of interventions. This is especially attractive when treating difficult or occlusive lesions.  Hotspur is setting a higher bar for peripheral and dialysis access angioplasty performance."

During the first procedure, Dr. Liu successfully restored blood flow through the patient's dialysis access graft by inflating a 7mm GPSCath™ balloon to 20ATM to open a blockage within the graft.  After performing the angioplasty, without removing the balloon, Dr. Liu then opened the proprietary valve on the distal end of the GPSCath™ balloon catheter and successfully injected contrast to visualize the angioplasty result. Dr. Liu followed with a second procedure performing both functions utilizing a 6mm GPSCath™ balloon. In the past for these types of treatments, physicians typically had to perform multiple catheter exchanges to open the vessels and visualize results, which can be time-consuming and expensive due to the use of multiple catheters. Hotspur's products aim to use one catheter for the entire procedure.

"We are committed to enabling medical professionals to perform peripheral access procedures with devices that both simplify and improve the doctors' and patients' experiences," said Gwen Watanabe, president and CEO of Hotspur.  "Our key goal is to bring innovation to markets that have had less focus because they are so fragmented."  Watanabe indicated that, based on recently released data, there are almost 20 million patients with peripheral vascular disease that could benefit from this multi-purpose approach to catheter design for the peripheral access market.

The GPSCath is the one of three Hotspur devices that have received 510(k) clearance from the U.S. Food and Drug Administration.  These devices are focused on solving some of the key challenges associated with restoring blood flow to blocked or low flow dialysis access grafts and fistulaes and peripheral vessels. In addition to the GPSCath™, the IQCath™ Balloon Dilatation Catheter is a specialty three-in-one device that allows the physician to perform angioplasty, embolectomy, and fluid injection with the same catheter while maintaining guidewire position; and the Keeper™ Embolectomy Catheter is a specialty two-in-one device that integrates an embolectomy balloon with the ability to inject physician-specified fluids while maintaining guidewire position.

These products are commercially available in the United States. The foundation of Hotspur's commercial devices is a groundbreaking technology known as the VisioValve™ injection system. This innovation utilizes a proprietary valve system that allows a physician to perform angioplasty or clot removal and perform an injection of physician-specified fluids without having to remove the guidewire or exchange devices. Hotspur expects to develop a variety of other treatment devices based on this technology.

About Hotspur TechnologiesFounded in 2008 and located in Mountain View, California, Hotspur Technologies (www.hotspur-inc.com) is a leading developer of catheter-based technologies aimed at restoring blood flow for patients with obstructed vessels. The company's products are based on a unique technology that opens blood vessels more efficiently and less invasively. The firm's VisioValve technology serves as a launching point to improve patient outcome and physician efficiency. Hotspur is privately held.  Its investors include ONSET Ventures, Finistere Ventures, BioStar Ventures, Saratoga Ventures, Incept, G-Level, and Versant Ventures.For more press information contact:
Abigail Johnson
Roeder-Johnson Corporation
(650) 802-1850
http://email.roeder-johnson.com

For more customer information contact:
Hotspur Technologies
Mountain View, CA
(650) 969-3150
info@hotspur-inc.com
'/>"/>

SOURCE Hotspur Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Hotspur Technologys Novel 3-in-1 Angioplasty Balloon Successfully Achieves First Commercial Deployment
2. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
3. King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction
4. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
5. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
6. New Clinical Studies Confirm Mauna Kea Technologies Cellvizio(R) GI in Range of Procedures
7. Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
8. Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
9. Senesco Technologies Initiates Preclinical Studies for Cancer Target
10. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
11. Epeius Biotechnologies Applauds the Belated Scholarship of Their Academic Contemporaries in 2007, As Targeted Gene Therapy Comes of Age in Clinical Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... , March 23, 2017  Ethicon* today ... Medical, Inc., a privately held medical device company ... System for the surgical treatment of Gastroesophageal Reflux ... strategy of expanding its portfolio of minimally invasive ... medical conditions. Financial terms of the transaction have ...
(Date:3/23/2017)... , March 23, 2017 CENTRO DE ... article 157, paragraph 4 of Law 6,404/76 and Instruction ... hereby informs its shareholders and the market in general ... its subsidiary Centro de Diagnosticos por Imagem Ltda. (" ... 100% interest in RADIOLOGISTAS ASSOCIADOS LTDA. (" Partnership " ...
(Date:3/23/2017)... 23, 2017  A new genetic test has ... of individuals who carry HLA-B*15:02 and ... yet potentially deadly side effect of certain medications ... gene HLA-B*15:02 is strongly associated with ... syndrome and toxic epidermal necrolysis in patients treated ...
Breaking Medicine Technology:
(Date:3/23/2017)... , ... March 23, 2017 , ... ... of SmartBen NOW, an innovative mobile app and centralized benefits dashboard solving one ... critical information securely from multiple locations. For the first time, employees can access ...
(Date:3/23/2017)... ... March 23, 2017 , ... The TouchPoint Solution, home ... world to manage stress and anxiety. , “Buzzies change the way we interact ... co-founder of Buzzies. , Since its launch date in December 2016, The TouchPoint Solution ...
(Date:3/23/2017)... ... 23, 2017 , ... Altec Products, Inc. , a ... their 2016 Microsoft Dynamics Partner of the Year at DocLink Evolution , ... recognizes The Resource Group for their outstanding relationship with Altec and their ability ...
(Date:3/23/2017)... ... March 23, 2017 , ... According to the National ... sleep is likely not the only cause of the sunken-eye look, which can include ... look older or in poor health are likely due to genetics, dehydration, allergies, and ...
(Date:3/23/2017)... El Segundo, CA (PRWEB) , ... March 23, ... ... Verisys FACIS Monthly Monitoring Healthcare products at competitive pricing. ... primary source sanctions, Exclusions, Debarments, License restrictions and Disciplinary actions. , “We are ...
Breaking Medicine News(10 mins):